Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced positive results from their DECISION trial of Nexavar (sorafenib) in patients with thyroid cancer.

The Phase III trial has met the primary endpoint of improving progression-free survival in patients with radioactive iodine refractory differentiated thyroid cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Bayer HealthCare global clinical development oncology vice president Dr Dimitris Voliotis said the results demonstrate Nexavar’s activity in RAI-refractory locally advanced, or metastatic differentiated thyroid cancer patients.

"These types of thyroid cancer are difficult to treat and are associated with a poor prognosis," Voliotis said.

"The Phase III trial has met the primary endpoint of improving progression-free survival in patients with radioactive iodine refractory differentiated thyroid cancer."

The multicentre, randomised study was designed to analyse the efficacy and safety of Nexavar compared to placebo in thyroid cancer patients who had received no earlier chemotherapy, tyrosine kinase inhibitors, or monoclonal antibodies against the disease.

See Also:

The placebo-controlled study randomised 417 patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer with 400mg of oral Nexavar twice daily or matching placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint was progression-free survival while the secondary endpoints included overall survival, time to progression, response rate and duration of response.

Study data is expected to form the basis for regulatory submission of Nexavar in treating RAI-refractory differentiated thyroid cancer.

Onyx clinical development senior vice president Dr Barbara Klencke said; "Effective treatment options are urgently needed for patients with radioactive iodine-refractory differentiated thyroid cancer."